Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1445]
News [2210]
Articles [39]
Editorials [5]
Conferences [150]
elearning [0]
‘Needless lives are being lost’ as charity reveals blood cancer survival in the UK is overshadowed by that in other countries
‘Needless lives are being lost’ as charity reveals blood cancer survival in the UK is overshadowed by that in...
FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for multiple myeloma
FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for multiple...
FDA grants accelerated approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma
FDA grants accelerated approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma
FDA-mandated CAR-T monitoring period could be halved
FDA-mandated CAR-T monitoring period could be halved
CHMP adopts positive opinion for erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations
CHMP adopts positive opinion for erdafitinib for the treatment of adult patients with unresectable or metastatic...
The Biden Cancer Moonshot announces more than $100 million in new actions to decrease the burden of cancer in Africa
The Biden Cancer Moonshot announces more than $100 million in new actions to decrease the burden of cancer in...
Preview: World Cancer Congress in Geneva
Preview: World Cancer Congress in Geneva
FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory follicular lymphoma
FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory follicular lymphoma
ASTRO issues clinical guideline on radiation therapy for patients with HPV-related throat cancer
ASTRO issues clinical guideline on radiation therapy for patients with HPV-related throat cancer
FDA approves durvalumab with chemotherapy for mismatch repair deficient primary advanced or recurrent endometrial cancer
FDA approves durvalumab with chemotherapy for mismatch repair deficient primary advanced or recurrent endometrial...

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation